NanoViricides files financial year end annual report with SEC

March 13, 2017

The Company also reported a significant expansion of its drug pipeline. The Company added two new drug programs and validated drug candidates to its pipeline, for Herpes Simplex Viruses and Dengue Viruses. The Company now has five commercially important drug development programs. FluCide(??)-I is a single drug in development against all forms of influenza A including bird flu, high path influenzas, epidemic influenzas, seasonal influenzas, and potentially any novel influenza A strains. HIVCide(??)-I is a drug in development against HIV/AIDS that shows the promise of becoming a "Functional Cure" against HIV/AIDS, based on available data. The Company is also developing a single topical solution nanoviricide to attack most viral infections of the eye including Epidemic Kerato-Conjunctivitis (EKC) and Herpes Keratitis. In addition, this year, the Company has successfully developed initial drug candidates against Oral "Cold Sores" and Genital Herpes. The Company also developed initial drug candidates against Dengue Viruses. These early drug candidates have already exhibited a substantial in vivo effectiveness of 50% survival of animals in an ADE-challenge model. ADE stands for antibody-dependent enhancement of dengue infection. This is a very serious effect which leads to severe dengue and fatalities in large numbers of patients that contract dengue virus of a different type after having had a dengue infection previously. There are currently no treatments or vaccines available for dengue or dengue hemorrhagic fever. We plan to improve these early anti-dengue and anti-HSV candidates further in the ensuing year and then advance into pre-IND application stage.

The Company believes that it has a robust, strong, and wide drug pipeline now.

"We have continued to obtain very strong results in our pre-clinical studies even as we engage new virus targets every year," said Anil R. Diwan, PhD, President and Chairman of the Company, adding, "This has demonstrated the strength of our technology, and enabled us to obtain further financing. We now plan to focus our work on advancing certain of our drug candidates into pre-IND applications. The pre-IND will enable us to have a dialog with the FDA for furthering the drugs into an IND stage."

"We now have the financial strength needed for the first step in advancing our drug candidates into the FDA regulatory process," said Eugene Seymour, MD, MPH, CEO of the Company.

Source: NanoViricides, Inc.

©2017 -